Alessio Di Prima | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up	LEUKEMIA & LYMPHOMA	2021
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab	ANNALS OF HEMATOLOGY	2021
Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia	BLOOD	2021
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients	ANNALS OF HEMATOLOGY	2021
Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors	CLINICAL DRUG INVESTIGATION	2020
Prognostic significance of PET/CT in patients with chronic lymphocytic leukemia (CLL) treated with frontline chemoimmunotherapy	CANCERS	2020
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice	EXPERT REVIEW OF HEMATOLOGY	2020
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2020
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience	ANNALS OF HEMATOLOGY	2020
The advantages and risks of ruxolitinib for the treatment of polycythemia vera	EXPERT REVIEW OF HEMATOLOGY	2020